Loss before income tax

6 Months Ended

Dec. 31, 2023

Disclosure Of Loss Before Income Tax [Abstract]


		Six Months Ended December 31,
(in U.S. dollars, in thousands)	Note	2023	2022
Revenue
Commercialization revenue		3,388	3,422
Total Revenue		3,388	3,422

Clinical trial and research & development		(2,045)	(4,067)
Manufacturing production & development		(5,484)	(11,717)

Employee benefits
Salaries and employee benefits		(10,096)	(9,842)
Defined contribution superannuation expenses		(199)	(186)
Equity settled share-based payment transactions(1)		(2,195)	(1,757)
Total Employee benefits		(12,490)	(11,785)

Depreciation and amortization of non-current assets
Plant and equipment depreciation		(281)	(565)
Right of use asset depreciation		(1,420)	(875)
Intellectual property amortization		(742)	(750)
Total Depreciation and amortization of non-current assets		(2,443)	(2,190)

Other Management & administration expenses
Overheads & administration		(4,594)	(5,187)
Consultancy		(1,285)	(1,967)
Legal and other professional fees		(1,124)	(1,053)
Intellectual property expenses (excluding the amount amortized above)		(1,410)	(1,505)
Total Other Management & administration expenses(2)		(8,413)	(9,712)

Fair value remeasurement of contingent consideration
Remeasurement of contingent consideration	5(e)(iii)	(337)	5,989
Total Fair value remeasurement of contingent consideration		(337)	5,989

Fair value remeasurement of warrant liability
Remeasurement of warrant liability	5(e)(vi)	4,434	(712)
Total Fair value remeasurement of warrant liability		4,434	(712)

Other operating income and expenses
Interest revenue		903	214
Foreign exchange gains/(losses)		165	(253)
Total Other operating income and expenses		1,068	(39)

Finance (costs)/gains
Remeasurement of borrowing arrangements		(120)	(1,230)
Interest expense		(10,199)	(9,455)
Total Finance costs		(10,319)	(10,685)

Total loss before income tax		(32,641)	(41,496)

(1)Share-based payment transactions

For the six months ended December 31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows:


	Six Months Ended December 31,
(in U.S. dollars)	2023	2022
Research and development	1,104,007	797,058
Manufacturing and commercialization	48,064	(183,720)
Management and administration	1,043,365	1,143,560
Equity settled share-based payment transactions	2,195,436	1,756,898

(2)Change in comparative figures

For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements.

Revenue recognition

Grünenthal arrangement

In September 2019, the Group entered into a strategic partnership with Grünenthal for the development and commercialization in Europe and Latin America of the Group’s allogeneic mesenchymal precursor cell (“MPC”) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease.

The Group received a non-refundable upfront payment of $15.0 million in October 2019, on signing of the contract with Grünenthal. The Group received a milestone payment in December 2019 of $2.5 million in relation to meeting a milestone event as part of the strategic partnership with Grünenthal.

In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Grünenthal has been amended, and milestone payments relating to R&D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$112.5 million prior to product launch in the EU, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$1 billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the agreement.

The $2.5 million milestone payment received in December 2019 from Grünenthal was considered deferred consideration as of December 31, 2023. The performance obligation for the $2.5 million was previously satisfied under the original agreement, however under the amended agreement with Grünenthal it is subject to repayment to Grünenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $2.5 million will no longer be subject to repayment to Grünenthal. For the six months ended December 31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to this strategic partnership with Grünenthal.

Tasly arrangement

In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (“Tasly”) for the development, manufacture and commercialization in China of the Group’s allogeneic mesenchymal precursor cell (“MPC”) products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China.

The Group received a $20.0 million up-front technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized $10.0 million from this $20.0 million up-front technology access fee at closing in

October 2018 and the remaining $10.0 million was recognized in revenue in February 2020. The Group is also entitled to receive $25.0 million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to six escalating milestone payments when the product candidates reach certain sales thresholds in China.

For the six months ended December 31, 2023 and 2022, respectively, no revenue was recognized in relation to this strategic alliance with Tasly.

TiGenix arrangement

In December 2017, the Group entered into a patent license agreement with TiGenix NV (“TiGenix”), now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived mesenchymal stem cell (“MSC") product, Alofisel® a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties.

The Group received a $5.9 million (€5.0 million) up-front payment upon entering the patent license agreement and a further payment of $5.9 million (€5.0 million) 12 months after the patent license agreement date. In September 2021, the Group received a milestone payment of $1.2 million (€1.0 million) upon Takeda receiving approval to manufacture and market Alofisel® in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's Disease. The Group is entitled to further payments up to €9.0 million when Takeda reaches certain product regulatory milestones. Additionally, the Group receives single digit royalties on net sales of Alofisel®.

For the six months ended December 31, 2023 and 2022, the Group earned $0.2 million and $0.2 million, respectively, of royalty income on sales of Alofisel® in Europe by our licensee Takeda.

For the six months ended December 31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to the Group's patent license agreement with Takeda.

JCR arrangement

In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris Therapeutics, Inc. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time.

Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (“EB”) in October 2018 and for hypoxic ischemic encephalopathy (“HIE”), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL® Hs. Inj. (“TEMCELL”), a registered trademark of JCR product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group apply the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied.

In the six months ended December 31, 2023, the Group recognized $3.2 million in commercialization revenue relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR, compared with $3.2 million for the six months ended December 31, 2022. These amounts were recorded in revenue as there are no further performance obligations required in regard to these items.

Inventories

Inventories are included in the financial statements at the lower of cost (including raw materials, direct labor, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 Inventories. Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 2 Inventories; the provision is then reversed at the point when a high probability of regulatory approval is determined.

The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate’s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends.

When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses.

All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for.

As of December 31, 2023, there was $21.6 million of pre-launch inventory recognized on the balance sheet that was fully provided for, compared with $22.4 million at June 30, 2023. The future commercial use of the pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for.

For the six months ended December 31, 2023, the Group reversed $0.8 million of pre-launch inventory costs within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory, primarily due to a reallocation of pre-launch inventory costs for use in clinical trials. For the six months ended December 31, 2022, $1.6 million of pre-launch inventory costs have been recognized within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory.